Disease · MONDO_0004728
Comparisons in its trials88
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 88
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| KSI-301 (Arm A) vs Aflibercept (Arm B): Percentage of Patients With a ≥ 2-step Worsening on the ETDRS DRSS in Studies KS301P104 and KS301P105 Combined | 6 of 433 | 3 of 437 | 870 | NCT04603937 | Trial comparisons |
| KSI-301 (Arm A) vs Aflibercept (Arm B): Percentage of Patients With a ≥ 2-step Worsening on the ETDRS DRSS in Studies KS301P104 and KS301P105 Combined | 6 of 433 | 3 of 437 | 870 | NCT04611152 | Trial comparisons |
| Ruboxistaurin vs Placebo: serious adverse events | 93 of 371 | 82 of 360 | 731 | NCT00090519 | Trial comparisons |
| Ruboxistaurin vs Placebo: serious adverse events | 145 of 345 | 157 of 340 | 685 | NCT00604383 | Trial comparisons |
| Brolucizumab 6mg q4w vs Aflibercept 2mg q4w: Number of Subjects With Non-ocular AEs (Greater Than or Equal to 2% in Any Treatment Arm) | 209 of 346 | 96 of 171 | 517 | NCT03917472 | Trial comparisons |
| KSI-301 (Arm A) vs Aflibercept (Arm B): deaths from any cause | 5 of 230 | 5 of 230 | 460 | NCT04611152 | Trial comparisons |
| KSI-301 (Arm A) vs Aflibercept (Arm B): serious adverse events | 61 of 230 | 51 of 230 | 460 | NCT04611152 | Trial comparisons |
| KSI-301 (Arm A) vs Aflibercept (Arm B): deaths from any cause | 4 of 228 | 6 of 229 | 457 | NCT04603937 | Trial comparisons |
| KSI-301 (Arm A) vs Aflibercept (Arm B): serious adverse events | 53 of 228 | 57 of 229 | 457 | NCT04603937 | Trial comparisons |
| KSI-301 (Arm A) vs Aflibercept (Arm B): Percentage of Patients With a ≥ 2-step Worsening on the ETDRS DRSS in Study KS301P105 | 6 of 218 | 3 of 218 | 436 | NCT04603937 | Trial comparisons |
| KSI-301 (Arm A) vs Aflibercept (Arm B): Percentage of Patients With a ≥ 2-step Worsening on the ETDRS DRSS in Study KS301P104 | 0 of 215 | 0 of 219 | 434 | NCT04611152 | Trial comparisons |
| Ranibizumab (RFB002) vs Laser: serious adverse events | 57 of 307 | 15 of 75 | 382 | NCT02259088 | Trial comparisons |
| Dexamethasone Intravitreal Implant vs Ranibizumab: serious adverse events | 40 of 181 | 41 of 182 | 363 | NCT01492400 | Trial comparisons |
| MYL-1701P vs Eylea: Number of Participants With Treatment Emergent Adverse Events | 138 of 178 | 138 of 176 | 354 | NCT03610646 | Trial comparisons |
| MYL-1701P vs Eylea: deaths from any cause | 2 of 178 | 4 of 176 | 354 | NCT03610646 | Trial comparisons |
| MYL-1701P vs Eylea: serious adverse events | 31 of 178 | 23 of 176 | 354 | NCT03610646 | Trial comparisons |
| MYL-1701P vs Eylea: Number of Subjects With Induced and Boosted Anti-Drug Antibodies | 5 of 177 | 10 of 176 | 353 | NCT03610646 | Trial comparisons |
| MYL-1701P vs Eylea: Number of Subjects Who Gained ≥15 Letters From Baseline in BCVA | 57 of 176 | 51 of 174 | 350 | NCT03610646 | Trial comparisons |
| CT-P42 vs Eylea: Proportion of Subjects With a ≥2-step Improvement From Baseline in the ETDRS DRSS (Diabetic Retinopathy Severity Score) as Assessed by FP (Fundus Photography) at Week 52 | 41 of 173 | 38 of 175 | 348 | NCT04739306 | Trial comparisons |
| CT-P42 vs Eylea: Proportion of Subjects Who Gained ≥15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 | 60 of 173 | 52 of 175 | 348 | NCT04739306 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004728/comparisons